Earendil Labs is an AI-powered biotechnology company that combines machine learning, generative protein engineering and high-throughput experimentation to design next-generation biologics for autoimmune and inflammatory diseases and cancer. It works alongside its affiliate Helixon Therapeutics and has collaborations with Sanofi and Genentech.
Phase 1 readouts for the anti-TSLP biparatopic antibody
Phase 2a data for HXN-1001 in ulcerative colitis
Genentech is paying $55 million upfront to work with AI biotech Earendil Labs to discover and develop several bispecific antibody cancer therapies, in a heavily backloaded deal that could top $1.5 billion.
Founder and Chief Executive Officer
President and co-Chief Executive Officer